The Approval Process in Action

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

For news on how catalysts affect specific stocks, read the updated Life Sciences Report Watchlist.

Fund Triples Holding of Drug Repurposing Firm
Source: Streetwise Reports (01/20/2022)

Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report.

Investment Highlights Company's Pivot From Fossil Fuels to Green Energy
Source: Streetwise Reports (01/19/2022)

Jericho Energy Ventures' latest foray into the burgeoning hydrogen energy market is as the lead seed capital investor in a company with disruptive electrolyzer technology.

Uranium Price Forecast 2022, Growth Expected
Source: Streetwise Reports (01/17/2022)

Political unrest in Kazakhstan and a buildup of stockpiles is leading to tightened demand and opportunities for growth in uranium, according to an industry report.

BC Junior Looks to Boost Status in Golden Triangle
Source: Streetwise Reports (01/15/2022)

If your neighbors sell their house, the sale price will tell you a lot about the value of your home. In British Columbia’s Golden Triangle, companies with mines and well-defined resource development plans are getting taken out and the remaining players — and their investors — can see the favorable writing on the wall.

Analyst Stands at Crossroads in 2022
Source: Michael Ballanger (01/11/2022)

With the accelerating involvement of government in the day-to-day behavior of all markets, it's a near-impossibility to forecast what will happen in 2022, Michael Ballanger says.